Monjuvi tafasitamab

Drug Class

CD19-directed monoclonal antibody

Mechanism

Binds CD19 expressed on pre-B and mature B lymphocytes, triggering ADCC and ADCP to eliminate neoplastic B-cells.

Approved Indication

In combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

What This Means For Patients

Monjuvi is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2020) — Sources
• EMA — Approved (2021) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• L-MIND — Salles et al., Lancet Oncol 2020 (NCT02399085) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi
• https://www.nmpa.gov.cn/